Literature DB >> 16516576

Impact of plasma aldosterone levels for prediction of in-stent restenosis.

Tetsuya Amano1, Tatsuaki Matsubara, Hideo Izawa, Masayuki Torigoe, Tomohiro Yoshida, Yukihisa Hamaguchi, Hideki Ishii, Manabu Miura, Yuzo Hayashi, Yasuhiro Ogawa, Toyoaki Murohara.   

Abstract

Aldosterone promotes vascular smooth muscle cell proliferation and endothelial dysfunction, suggesting the contribution to in-stent restenosis (ISR). This study evaluated any relation between plasma aldosterone levels and ISR 6 months after successful coronary stenting. We enrolled 156 consecutive patients with stable angina who underwent coronary bare metal stenting. Plasma aldosterone levels and other serum markers known to influence cardiovascular events were measured in all patients at baseline. Patients with restenosis were found to have significantly higher plasma aldosterone levels than their counterparts without restenosis (162 +/- 60 vs 122 +/- 60 pg/ml, p = 0.007). On logistic regression analysis, even after adjusting for clinical, angiographic, and other confounding variables, plasma aldosterone level per 10 pg/ml (odds ratio 1.34, 95% confidence interval 1.10 to 1.63, p = 0.006) proved to be the independent predictor of ISR. The area under the receiver-operating characteristic curve for plasma aldosterone level was 0.75, and the optimal cut-off value identified by receiver-operating characteristic analysis was 141.9 pg/ml, which had a predictive accuracy of 69%. In conclusion, the present findings indicate that plasma aldosterone levels at baseline are independent predictors of ISR and may constitute a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516576     DOI: 10.1016/j.amjcard.2005.10.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.

Authors:  Mindy Markowitz; Frank Messineo; Neil L Coplan
Journal:  Clin Cardiol       Date:  2012-07-06       Impact factor: 2.882

Review 2.  Mineralocorticoid antagonism and cardiac hypertrophy.

Authors:  Kohzo Nagata
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

Authors:  Yasuhiro Nakamura; Saya Suzuki; Takashi Suzuki; Katsuhiko Ono; Ikumi Miura; Fumitoshi Satoh; Takuya Moriya; Haruo Saito; Shogo Yamada; Sadayoshi Ito; Hironobu Sasano
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Aortic cell apoptosis in rat primary aldosteronism model.

Authors:  Yongji Yan; Jinzhi Ouyang; Chao Wang; Zhun Wu; Xin Ma; Hongzhao Li; Hua Xu; Zheng Hu; Jun Li; Baojun Wang; Taoping Shi; Daojing Gong; Dong Ni; Xu Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-06-17

5.  The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.

Authors:  Jochen Dutzmann; Robert-Jonathan Musmann; Marco Haertlé; Jan-Marcus Daniel; Kristina Sonnenschein; Andreas Schäfer; Peter Kolkhof; Johann Bauersachs; Daniel G Sedding
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

6.  Elevated plasma aldosterone levels are associated with a reduction in retinal ganglion cell survival.

Authors:  Yukari Takasago; Kazuyuki Hirooka; Yuki Nakano; Mamoru Kobayashi; Aoi Ono
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Jul-Sep       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.